2) plasminogen activator
纤溶酶原激活物
1.
Correlation of plasminogen activator and plasminogen active inhibitor expression and capillary density in IgA nephropathy.;
纤溶酶原激活物及其抑制剂-1表达与IgA肾病毛细血管密度相关关系的研究
2.
The relationship between the dynamic change of plasma plasminogen activator and its inhibitor-1 levels and infarct size in patients with acute cerebral infarction;
急性脑梗死患者血浆纤溶酶原激活物及其抑制剂-1水平的动态变化及其与梗死面积的关系
3.
Detection of Plasminogen activator and thrombomodulin in lung cancer patients and its clinical significance;
肺癌患者纤溶酶原激活物和血栓调节蛋白检测分析
3) activator of plasminogen
纤溶酶原激活物
1.
Effects of NaoMaiTong combined with thrombolysis on activator of plasminogen and its receptor in rats with thrombus-occluded cerebral ischemia;
脑脉通联合溶栓对血栓栓塞性脑缺血大鼠纤溶酶原激活物及其受体的影响
4) urokinase-type plasminogen activator
尿激酶纤溶酶原激活物
1.
Aim: To investigate the expression of urokinase-type plasminogen activator (uPA) in human colorectal carcinoma tissue and its relation to the neovascularization.
目的检测大肠癌组织中尿激酶纤溶酶原激活物(uPA)及微血管密度(MVD)。
2.
The protein level of urokinase-type plasminogen activator (uPA) was also determined by western blotting.
采用Western blot方法检测癌细胞尿激酶纤溶酶原激活物(uPA)蛋白水平。
3.
Besides,the protein level of urokinase-type plasminogen activator(uPA) was also determined by Western blot assay.
另外,采用Western blot方法检测癌细胞尿激酶纤溶酶原激活物(urokinase-type plasminogen activator,uPA)蛋白变化。
5) plasminogen activator inhibitor-1
纤溶酶原激活物抑制物
1.
Objective:To analyze the plasma levels of tissue plasminogen activator(t-PA) and plasminogen activator inhibitor-1(PAI-1) in patients with coronary heart disease(CHD) and to assess its clinical implications.
方法:回顾性分析本院222例冠心病患者血浆组织型纤溶酶原激活物(t-PA)及纤溶酶原激活物抑制物-1(PAI-1)水平。
2.
ObjectiveTo evaluate the plasminogen activator system (plasminogen activator inhibitor-1 and tissue plasminogen activator) in women with PCOS and compared in groups .
目的:探讨纤溶酶原激活物抑制物-1(PAI-1)和组织型纤溶酶原激活物(t-PA)的高低与多囊卵巢综合征(polycystic ovary syndrome, PCOS)患者病变发展之间的关系以探寻一较好的监测指标。
3.
Objective To investigate the role of rosiglitazone in improving blood lipids and proteinuria in rats with Type 2 diabete,and the effect of rosiglitazone on expressions of plasminogen activator inhibitor-1 in kidney of streptozotocin-diabetic rats.
目的研究罗格列酮对2型糖尿病大鼠血糖血脂的影响及肾皮质纤溶酶原激活物抑制物1(PAI-1)表达的作用。
6) plasminogen activator inhibitor
纤溶酶原激活物抑制物
1.
Objective To observe the influence of Shenluotong on the protein expression of plasminogen activator inhibitor 1(PAI-1) in kidney remaining tissue in rats with kidney failure induced by 5/6 of nephrectomy.
目的观察肾络通对5/6肾切除肾衰竭大鼠残余肾组织纤溶酶原激活物抑制物-1(PAI-1)蛋白表达的影响。
2.
The activities of tissue plasminogen activator(tPA),plasminogen activator inhibitor(PAI) and plasminogen(PLG) in plasma were determined by chromogenic substrate assay,and thrombi weight was measured.
先给大鼠喂药后以FeCl3诱导左侧颈总动脉血栓形成,以发色底物法测定血浆组织型纤溶酶原激活物(tPA)、纤溶酶原激活物抑制物(PAI)和纤溶酶原(PLG)活性,并测定血栓质量。
3.
Objective To investigate the changes of serum plasminogen activator inhibitor(PAI),D-dimer and thrombomodulin(TM),and the relationship between these changes and phlegm syndrome or blood-stasis syndrome in patients with acute cerebral infarction.
目的探讨急性脑梗死患者血浆纤溶酶原激活物抑制物(PAI)、D-二聚体、血栓调节蛋白(TM)变化与中医痰证、血瘀证变化的关系。
补充资料：乙酰化纤溶酶原-链激酶激活剂复合物
药物名称：乙酰化纤溶酶原-链激酶激活剂复合物
英文名：APSAC
该药对血块有选择性高亲和力且半衰期长，清除半衰期为70分钟，故纤维蛋白溶解作用缓慢而持久。用药后5-8小时仍可维持有效溶栓血药浓度，有报告作用维持7-10天，而SK用药后3小时血中即完全清除，因此可视为长效SK。
APSAC用药特点是短RV间内一次给予全部剂量。据报告冠状动脉内溶栓5分钟内注射5-30mg，1-4小时后闭塞动脉再通率为70-83％。静脉给药5分钟内注入5-30mg，再通率为60-100％。该药全身纤溶作用微弱，用药简单，药物作用时间长，然而再闭塞率可达20％，但平均再闭塞率仍较SK、rt-PA为低。
类别：溶栓药
英文名：APSAC
该药对血块有选择性高亲和力且半衰期长，清除半衰期为70分钟，故纤维蛋白溶解作用缓慢而持久。用药后5-8小时仍可维持有效溶栓血药浓度，有报告作用维持7-10天，而SK用药后3小时血中即完全清除，因此可视为长效SK。
APSAC用药特点是短RV间内一次给予全部剂量。据报告冠状动脉内溶栓5分钟内注射5-30mg，1-4小时后闭塞动脉再通率为70-83％。静脉给药5分钟内注入5-30mg，再通率为60-100％。该药全身纤溶作用微弱，用药简单，药物作用时间长，然而再闭塞率可达20％，但平均再闭塞率仍较SK、rt-PA为低。
类别：溶栓药
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条